Related Experiment Video

Updated: May 24, 2026

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

[Norcantharidin potentialize the chemosensitivity of adriamycin through the NF-κB/IκBα signaling pathway]

Xiao-ning Song1, Heng-fei Du, Lu-jia Yu

  • 1Department of Hematology, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China.

Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi
|February 21, 2012
PubMed
Abstract

Insights

Norcantharidin (NCTD) enhances adriamycin (ADR) effectiveness against multiple myeloma (MM) cells by promoting apoptosis and reducing proliferation. This synergy involves regulating the NF-κB/IκBα pathway and key related genes.

Area of Science:

  • Pharmacology and Molecular Biology
  • Cancer Research
  • Hematology

Background:

  • Multiple myeloma (MM) is a hematological malignancy with limited treatment options.
  • Adriamycin (ADR) is a chemotherapeutic agent used in MM treatment.
  • Norcantharidin (NCTD) is a derivative with potential anti-cancer properties.

Purpose of the Study:

  • To investigate the synergistic effects of NCTD and ADR on MM cell proliferation and apoptosis.
  • To elucidate the underlying molecular mechanisms, including the NF-κB signaling pathway.

Main Methods:

  • U266 MM cells were treated with NCTD alone or in combination with ADR.
  • Cell viability and apoptosis were assessed using MTT assays and Annexin V/PI staining.
  • Protein expression of NF-κB P65, p-NF-κB p65, IκBα, p-IκBα, survivin, Bcl-2, and Bax was analyzed by Western blot.
  • Vascular endothelial growth factor (VEGF) expression was evaluated using immunohistochemistry.

Main Results:

  • NCTD significantly potentiated ADR's cytotoxicity and pro-apoptotic effects, demonstrating a synergistic anti-proliferation effect.
  • The combination downregulated nuclear NF-κB P65 and cytoplasmic p-IκBα, while cytoplasmic NF-κB P65 and IκBα remained unchanged.
  • Expression of survivin and Bcl-2 decreased, while Bax expression increased in the combination group compared to ADR alone.
  • NCTD enhanced ADR's inhibitory effect on VEGF expression.

Conclusions:

  • NCTD potentiates the chemosensitivity of multiple myeloma cells to ADR.
  • The synergistic effect is mediated through the regulation of the NF-κB/IκBα signaling pathway.
  • NCTD modulates NF-κB-regulated genes, including survivin, Bcl-2, Bax, and VEGF, contributing to enhanced anti-cancer activity.

More Related Videos

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity07:58

An Automated Differential Nuclear Staining Assay for Accurate Determination of Mitocan Cytotoxicity

Published on: May 12, 2020

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
NF-kB-dependent Signaling Pathway02:26

NF-kB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...